Sign In
Buy PROG
$0.94
-0.0340 (-3.48%)
At Close: Aug 17, 2022
Progenity Announces $25 Million Private Placement
07:45am, Tuesday, 23'rd Feb 2021
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mol
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Progenity, Inc. - PROG
02:22pm, Monday, 22'nd Feb 2021
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG
12:25am, Friday, 19'th Feb 2021
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to con
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
07:30am, Wednesday, 17'th Feb 2021
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing produc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG
09:53pm, Monday, 15'th Feb 2021
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
07:30am, Friday, 12'th Feb 2021
Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Pre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG
01:47pm, Thursday, 11'th Feb 2021
New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors
Progenity to Participate in Two Upcoming Investor Conferences
07:30am, Wednesday, 10'th Feb 2021
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Why Progenity's Stock is Down During Today's Session
10:06am, Monday, 08'th Feb 2021
Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volume averag
Progenity Reaches Two Million Test Milestone
07:30am, Wednesday, 20'th Jan 2021
The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations
Progenity Provides Financial Guidance for Full-year 2021
04:05pm, Wednesday, 13'th Jan 2021
Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million
Progenity to Present at the 2021 ICR Conference
07:30am, Tuesday, 05'th Jan 2021
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
07:30am, Thursday, 17'th Dec 2020
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity Announces Closing of Public Offering of Common Stock
07:30am, Tuesday, 08'th Dec 2020
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mo
